[논문]Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma

Lee, Ki Rim; Koh, Jiwon; Jeon, Yoon Kyung; Kwon, Hyun Jung; Lee, Jeong-Ok; Paik, Jin Ho

doi:10.4132/jptm.2021.10.05

[국내논문] Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma 원문보기

Journal of pathology and translational medicine : JPTM, v.56 no.1, 2022년, pp.32 - 39

Lee, Ki Rim (Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea) , Koh, Jiwon (Department of Pathology, Seoul National University College of Medicine, Seoul, Korea) , Jeon, Yoon Kyung (Department of Pathology, Seoul National University College of Medicine, Seoul, Korea) , Kwon, Hyun Jung (Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea) , Lee, Jeong-Ok (Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea) , Paik, Jin Ho (Department of Pathology, Seoul National University Bundang Hospital, Seongnam, Korea)

Abstract ▼ AI-Helper

BackgroundPrimary adrenal (PA) diffuse large B cell lymphoma (DLBCL) was previously reported as an aggressive subset of DLBCL, but its genetic features were not sufficiently characterized. From our previous study of DLBCL with programmed death-ligand 1 (PD-L1) gene alterations, we focused on PD-L1 gene alterations in PA-DLBCL with clinicopathologic implications.MethodsWe performed fluorescence in situ hybridization for PD-L1 gene translocation and amplification in PA-DLBCL (n = 18) and comparatively analyzed clinicopathologic characteristics with systemic non-adrenal (NA)-DLBCL (n = 90).ResultsPA-DLBCL harbored distinctive features (vs. NA-DLBCL), including high international prognostic index score (3–5) (72% [13/18] vs. 38% [34/90], p = .007), poor Eastern Cooperative Oncology Group performance score (≥ 2) (47% [7/15] vs. 11% [10/90], p = .003), elevated serum lactate dehydrogenase (LDH) (78% [14/18] vs. 51% [44/87], p = .035) and MUM1 expression (87% [13/15] vs. 60% [54/90], p = .047). Moreover, PA-DLBCL showed frequent PD-L1 gene alterations (vs. NA-DLBCL) (39% [7/18] vs. 6% [5/86], p = .001), including translocation (22% [4/18] vs. 3% [3/87], p = .016) and amplification (17% [3/18] vs. 2% [2/87], p = .034). Within the PA-DLBCL group, PD-L1 gene–altered cases (vs. non-altered cases) tended to have B symptoms (p = .145) and elevated LDH (p = .119) but less frequent bulky disease (≥ 10 cm) (p = .119). In the survival analysis, PA-DLBCL had a poor prognosis for overall survival (OS) and progression-free survival (PFS) (vs. NA-DLBCL; p = .014 and p = .004). Within the PA-DLBCL group, PD-L1 translocation was associated with shorter OS and PFS (p < .001 and p = .012).ConclusionsPA-DLBCL is a clinically aggressive and distinct subset of DLBCL with frequent PD-L1 gene alterations. PD-L1 gene translocation was associated with poor prognosis in PA-DLBCL.

주제어

참고문헌 (22)

1 Swerdlow SH Campo E Pileri SA The 2016 revision of the World Health Organization classification of lymphoid neoplasms Blood 2016 127 2375 90 26980727

상세보기
2 Nagasaki J Togashi Y Sugawara T The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma Blood Adv 2020 4 4069 82 32870971

상세보기
3 Xu-Monette ZY Zhou J Young KH PD-1 expression and clinical PD-1 blockade in B-cell lymphomas Blood 2018 131 68 83 29118007

상세보기
4 Roemer MG Advani RH Ligon AH PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome J Clin Oncol 2016 34 2690 7 27069084

상세보기
5 Ansell SM Lesokhin AM Borrello I PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma N Engl J Med 2015 372 311 9 25482239

상세보기
6 Kwon HJ Yang JM Lee JO Lee JS Paik JH Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma J Transl Med 2018 16 320 30458835

상세보기
7 Twa DD Chan FC Ben-Neriah S Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma Blood 2014 123 2062 5 24497532

상세보기
8 Chapuy B Roemer MG Stewart C Targetable genetic features of primary testicular and primary central nervous system lymphomas Blood 2016 127 869 81 26702065

상세보기
9 Cohen R Jonchere V De La Fouchardiere C Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer J Immunother Cancer 2021 9 e001903 33579738

상세보기
10 Mushtaq RR Gao D Raeburn C Tobin RP Robinson W Adrenal metastases in malignant melanoma, is it a privileged site? J Clin Oncol 2019 37 15 Suppl e21016
11 Rashidi A Fisher SI Primary adrenal lymphoma: a systematic review Ann Hematol 2013 92 1583 93 23771429
12 Kim YR Kim JS Min YH Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL) J Hematol Oncol 2012 5 49 22889180

상세보기
13 Laurent C Casasnovas O Martin L Adrenal lymphoma: presentation, management and prognosis QJM 2017 110 103 9 27795295

상세보기
14 Mozos A Ye H Chuang WY Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis Mod Pathol 2009 22 1210 7 19525926

상세보기
15 Audrito V Serra S Stingi A PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p Oncotarget 2017 8 15894 911 28199980

상세보기
16 Gao Q Wang XY Qiu SJ Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma Clin Cancer Res 2009 15 971 9 19188168

상세보기
17 Hans CP Weisenburger DD Greiner TC Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Blood 2004 103 275 82 14504078

상세보기
18 Bardhan K Anagnostou T Boussiotis VA The PD1:PD-L1/2 pathway from discovery to clinical implementation Front Immunol 2016 7 550 28018338
19 Hudson K Cross N Jordan-Mahy N Leyland R The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment Front Immunol 2020 11 568931 33193345
20 Pasqualucci L Dalla-Favera R The genetic landscape of diffuse large B-cell lymphoma Semin Hematol 2015 52 67 76 25805586

상세보기
21 Iqbal J Greiner TC Patel K Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma Leukemia 2007 21 2332 43 17625604

상세보기
22 Peng C Hu Q Yang F Zhang H Li F Huang C BCL6-mediated silencing of PD-1 ligands in germinal center B cells maintains follicular T cell population J Immunol 2019 202 704 13 30567732

상세보기

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

[국내논문] Clinicopathologic implication of PD-L1 gene alteration in primary adrenal diffuse large B cell lymphoma 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (22)

이 논문을 인용한 문헌

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트